In this advocacy note, IDPC offers some analysis and key recommendations on CBD and tramadol to inform the ECDD’s meeting set to take place in November 2017.
This IDPC progress report provides an overview of our activities between 2016 and 2017, including our continuing efforts to build capacity for drug policy advocacy and the numerous publications and resources produced during this period.
This EMCDDA report presents a brief overview of recent evidence for the most effective approaches in the fields of drug use prevention, drug use treatment and harm reduction.
The EMCDDA sheds light on the specific challenges affecting women who use drugs, gaps in knowledge and policy recommendations for policies and practices to be gender mainstreamed.
UNAIDS and UNFPA have consulted with a broad range of stakeholders to produce a document that identifies key avenues towards the attainment of the 2030 goals.
Complemented by other activities implemented in nightlife settings, drug checking can serve as an extension of prevention and harm reduction interventions, potentially saving lives.
The research estimates that there are 15.6 million people who inject drugs aged 15-64 years globally, with a substantial number living with HIV and HCV, and exposed to adverse risk environments that increase health harms.
IDPC calls upon the OHCHR to promote harm reduction, reiterate its call for the decriminalisation of drug use and end all other forms of inhumane and disproportionate punishment.
The authors conclude that HIV and HCV prevention interventions for people who inject drugs remains poor and is likely to be insufficient to effectively prevent HIV and HCV transmission.
